Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
Dihydropyrimidine dehydrogenase (DPD) is a metabolic enzyme that is crucial in 5-fluorouracil (5-FU) degradation. A deficiency in it is associated with the occurrence of adverse events following fluoropyrimidine-based therapies. We describe a case of toxicity grade 5 after the administration of capecitabine and oxaliplatin in a patient with stage III colorectal cancer and DPD congenital deficiency, which was identified later. Several polymorphisms have been associated with the global toxicity of 5-FU; however, genetic tests are low in sensitivity and therefore they cannot as yet be used as prescreening techniques in clinical practice.
Medical Oncology Department, Hospital Regional Universitario, Malaga, Spain.
Maria José
MJ
Bermejo-Pérez
Ana Maria
AM
Galeote-Miguel
Luis Enrique
LE
Rodelo-Haad
Inmaculada
I
Alés-Díaz
Gema
G
Durán-Ogalla
Manuel
M
Benavides-Orgaz
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000069287:Capecitabine / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D054067:Dihydropyrimidine Dehydrogenase Deficiency / Q000139:chemically induced* / Q000175:diagnosis*; D017809:Fatal Outcome; D005260:Female; D006801:Humans
D000964:Antimetabolites, Antineoplastic; D000069287:Capecitabine